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Abstract
Background: The prevailing paradigm in cancer research is the somatic mutation theory that
posits that cancer begins with a single mutation in a somatic cell followed by successive mutations.
Much cancer research involves refining the somatic mutation theory with an ever increasing catalog
of genetic changes. The problem is that such research may miss paradoxical aspects of
carcinogenesis for which there is no likely explanation under the somatic mutation theory. These
paradoxical aspects offer opportunities for new research directions that should not be ignored.
Discussion: Various paradoxes related to the somatic mutation theory of carcinogenesis are
discussed: (1) the presence of large numbers of spatially distinct precancerous lesions at the onset
of promotion, (2) the large number of genetic instabilities found in hyperplastic polyps not
considered cancer, (3) spontaneous regression, (4) higher incidence of cancer in patients with
xeroderma pigmentosa but not in patients with other comparable defects in DNA repair, (5) lower
incidence of many cancers except leukemia and testicular cancer in patients with Down's
syndrome, (6) cancer developing after normal tissue is transplanted to other parts of the body or
next to stroma previously exposed to carcinogens, (7) the lack of tumors when epithelial cells
exposed to a carcinogen were transplanted next to normal stroma, (8) the development of cancers
when Millipore filters of various pore sizes were was inserted under the skin of rats, but only if the
holes were sufficiently small. For the latter paradox, a microarray experiment is proposed to try
to better understand the phenomena.
Summary: The famous physicist Niels Bohr said "How wonderful that we have met with a
paradox. Now we have some hope of making progress." The same viewpoint should apply to
cancer research. It is easy to ignore this piece of wisdom about the means to advance knowledge,
but we do so at our peril.
Background
Many scientists spend their careers performing studies
designed to refine the knowledge base of existing para-
digms of their science. Therefore much research is con-
servative in the sense that it tries to patch small holes in
the existing paradigm, running the risk of ignoring gaping
chasms. The prevailing paradigm in cancer research is the
somatic mutation theory (SMT) that posits that cancer
begins with a single mutation in a somatic cell followed
by successive mutations [1]. Much current cancer research
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involves cataloging the ever increasing menagerie of
genetic changes associated with cancer and trying to
explain how they synergistically account for cancer phe-
notypes. This process of building ever more elaborate
genetic models of carcinogenesis has been likened to add-
ing epicycle models to the pre-Copernican Ptolemeic par-
adigm of planetary motion in order to explain
discrepancies in astronomical data without postulating
that the earth revolves around the sun [2]. The description
of the motion of each newly discovered planetary body
had to be retrofitted to Ptolemy's theory of "planetary per-
fection" [3]. While it is commendable to pursue a particu-
lar line of research to fill small cracks in theory, there is a
problem when such a focus leads researchers to ignore the
larger fissures that challenge the entire edifice. As we dis-
cuss, under SMT, there are paradoxical results involving
initiation and promotion experiments, genetic instabili-
ties, spontaneous regression, transplantation experi-
ments, and foreign-body carcinogenesis. In our view
ignoring these paradoxes misses a golden opportunity for
new insights. We believe there should always be provision
for "paradox-driven" research initiatives. In fact, the direc-
tor of the U.S. National Institutes of Health, Dr. Elias
Zerhouni, has recently initiated an innovation awards
funding mechanism in this very spirit [4].
Discussion
A result is paradoxical when the prevailing theory offers
no likely explanation. When investigating reproducible,
paradoxical results, it is helpful to consider alternative
theories. One alternative to SMT is tissue organization
field theory (TOFT) that posits that cancer arises from
defects in cell communication often, but not necessarily,
between the parenchyma, the functional tissue where
most cancers arise, and the stroma, the surrounding con-
nective tissue [2,5,6]. Results that are paradoxical under
SMT may not be paradoxical under TOFT. Regardless of
the validity of TOFT, the consideration of this alternate
theory can be an important impetus for new research. To
better illustrate how a paradox can lead to new study
designs, we propose a microarray experiment to investi-
gate the paradoxical results from experiments in plastic-
film carcinogenesis.
Paradoxes in initiation and promotion experiments
Initiation and promotion refer to observations about car-
cinogenesis in the following context: when investigators
apply two particular treatments to the skin of rats at some
time apart, the rats develop cancers at the location of the
treatments; these localized cancers appear only after the
application of the second treatment and do not develop
when the order of treatments is reversed. The first treat-
ment has been called the initiator and the second the pro-
moter and the corresponding effects are called initiation
and promotion. These experiments suggest that the initia-
tor induces an irreversible persistent change [7]. Under
the SMT the explanation is clear: the irreversible persistent
change is a mutation of the genes in a skin cell. This expla-
nation has become virtually axiomatic in the field of can-
cer research.
However some of these experiments reveal a paradoxical
result under SMT, namely the presence of large numbers
of spatially distinct precancerous lesions at the onset of
promotion [8]. This phenomena is called field canceriza-
tion and its explanation is an important unanswered
question under SMT [9]. One SMT explanation is that
each precancerous lesion arises from a separate mutation;
another SMT explanation is that a single genetic event
occurs in a cell that clonally expands and migrates to other
sites [9]. A TOFT explanation is that initiation creates an
irreversible non-mutational change in the field of stromal
tissue and promotion acts on the initiated stromal tissue
to alter communication to many cells in the skin paren-
chyma. The current dominance of experiments on cell
lines, tissue culture, and tumors locks the focus on the
cancer cell, at the expense of surrounding stroma. What-
ever the explanation, detailed study of these precancerous
lesions would be an illuminating topic for additional
research.
Paradoxes in genetic instability in cancer and 
precancerous cells
It is well known that cancer cells exhibit numerous
genomic alterations, which are sometimes called genetic
instability. Under the SMT, the genetic mutations arise as
part of a stochastic cascade of mutations on the way from
an initial mutated cell to malignant cancer. The paradoxi-
cal results are the large number of genetic instabilities also
found in benign neoplasms and hyperplastic polyps that
are not considered cancers or even premalignant [10,11].
The most likely SMT explanation is multiple mutations,
which is inconsistent with the generally accepted view
that mutations are rare. A TOFT explanation is that the
genetic instability of tumors is a consequence, not a cause,
of cancer. One model consistent with TOFT postulates
that the defect in cell communication directly alters gene
expression leading to inactivated DNA segments that are
not repaired under normal processes, yielding an accumu-
lation of mutations [12]. This model makes biological
sense because cells would not waste energy repairing inac-
tivated DNA of little functional consequence [12]. Sup-
port for this model comes from experiments showing that
repair of mutations caused by ultraviolet radiation was
more efficient in expressed versus silent genes [12,13].
Support for the TOFT explanation also comes from exper-
iments showing that initiation of cancer by an altered
stromal environment resulted in genetic instabilities [14].
Trying to determine if genetic instabilities are a cause or an
effect of cancer would make a fruitful research enterprise.BMC Cancer 2007, 7:151 http://www.biomedcentral.com/1471-2407/7/151
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Paradoxes in spontaneous regression
In rare cases, some tumors regress spontaneously. Under
SMT, spontaneous regression might be explained by the
extinction of cells carrying the mutation [15], but the
details are not known. Under TOFT spontaneous regres-
sion can arise if the normal reciprocal intercellular signals
are no longer disrupted. Because spontaneous regression
is rare (frequent spontaneous differentiation of screening
detected neuroblastoma of infancy is a notable excep-
tion), research on spontaneous regression in human can-
cer is difficult. However animal models and three
dimensional cultures [16] could provide promising ave-
nues for additional research along these lines. Also a
related phenomenon, the replacement of the intraductal
component of breast cancer by fibrous tissue, was
observed in 21 of 311 patients undergoing breast conser-
vation therapy [17]. A molecular study of these phenom-
ena might yield promising leads.
Paradoxes involving inherited mutations related to DNA 
repair
Fibroblasts from patients with xeroderma pigmentosa
have a defect in repairing DNA damage that is either
caused by some chemicals or ultraviolet light. If DNA
damage were directly causing cancer, one would expect
that exposure to ultraviolet light would increase the risk of
skin cancer and exposure to chemicals in the environment
would increase the risk of other cancers, so it is puzzling
that patients with xeroderma pigmentosa have elevated
rates of skin cancer but not elevated rates of other types of
cancer [18]. Further investigation is also need to explain
why patients with Cockayne syndrome and trichothiodys-
trophy have no increased rates of skin cancers although
they have a comparable defect in DNA repair [19].
Paradoxes involving Down's syndrome
Another paradoxical result is that persons with Down's
syndrome are at much higher risk than the general popu-
lation for leukemia and testicular cancer, but paradoxi-
cally at much lower risk for solid tumors, particularly
breast cancer. When interpreting epidemiological studies
that report incidence rates of many cancers, one must con-
sider the possibility of finding an extreme cancer inci-
dence rate by chance simply because incidence rates in
many cancers were examined – the "multiple compari-
sons problem." Here the possibility of a chance result is
diminished because the results are derived from three
studies. The first study published in 2000 can be viewed as
hypothesis generating; its main finding was that, among
2084 Danish persons with Down's syndrome, the inci-
dence of leukemia was higher than the general population
and the incidence of solid tumors (particularly breast can-
cer) was lower than in the general population [20]. A
study published in 2002 involving 17897 Americans with
Down's syndrome confirmed the higher incidence of
leukemia and the lower incidence of solid tumors, partic-
ularly breast cancer; it also noted a higher incidence of tes-
ticular cancer (which had also been elevated in the
previous study) [21]. A study published in 2006 involving
3581 persons in Finland with Down's syndrome also
reported higher risk of leukemia and testicular cancer and
lower risk of solid tumors than in the general population
[22].
The striking aspect of the aforementioned results is that
the solid   cancers, which have a lower incidence in people
with Down's syndrome,   are surrounded by stromal cells
while leukemia and testicular   cancers, which have a
higher incidence in people with Down's   syndrome, are
either devoid of stroma or have poorly developed stroma.
These results, which have no obvious SMT explanation,
point to a connection between the stroma and cancer inci-
dence, which would be consistent with TOFT. Further
experimentation, prompted by these results, has been pro-
posed to study the extracellular components in patients
with Down's syndrome in relationship to the formation
of breast cancer [23].
Paradoxes in transplantation carcinogenesis
Some transplantation experiments have involved normal
cells transplanted to other parts of the body or next to
stroma previously exposed to a carcinogen. When normal
murine ovary tissue is transplanted to the spleen, many of
the mice with transplanted tissues develop cancer [18].
When normal rat mammary epithelial cells were trans-
planted next to stroma exposed to a chemical carcinogen
(after previously clearing out the local epithelial cells),
cancer developed in the epithelial cells at a much higher
rate than in controls [24]. Also, in vivo experiments have
shown that when unirradiated murine epithelial cells
were transplanted next to the irradiated stroma (after pre-
viously clearing out the epithelial cells), cancer developed
in the unirradiated cells at a much higher rate than in con-
trols [25]. Other transplantation experiments have
involved cancer cells or cells exposed to carcinogen trans-
planted to other parts of the body. When mouse teratocar-
cinoma cells were transplanted to normal mouse embryo,
they had stable differentiation and were incorporated into
the tissue [26]. When murine skin epithelial cells exposed
to a carcinogen that would normally cause tumors in a few
weeks were transplanted to an untreated site, no tumors
developed [27]. SMT does not offer a likely explanation
but a TOFT explanation of altered communication from
the stroma to the parenchyma is clear. This  active area of
research should be pursued. Microarray studies (as dis-
cussed in the next section) could be useful tools to try to
understand the mechanism underlying these results.BMC Cancer 2007, 7:151 http://www.biomedcentral.com/1471-2407/7/151
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Paradoxes in foreign-body carcinogenesis
The discovery that materials inserted subcutaneously in
animals can induce cancer was found serendipitously in
the 1940's and was confirmed in experiments in the
1950's and 1960's. A primary finding was a similar carci-
nogenic response for various substances (including highly
unreactive materials such as gold, platinum, and polyeth-
ylene) inserted subcutaneously, but only when they were
implanted intact and not in a powdered form [28].
Lest one think that these experiments are artificial, there is
speculation that the same mechanism could be responsi-
ble for the development of gallbladder cancers, which are
strongly associated with the presence of gallstones, lung
cancer arising near scar tissue ("scar cancers"), and lung
cancer in smokers. Regarding the latter, in 1962, Passey
wrote "my heresy is to believe that the excess of mucoid
secretion, so often found in respiratory disease, is the con-
dition responsible for many lung cancers. Mucus is sticky
and will cling to a patch of respiratory epithelium for
longer periods: by its blanketing action – occlusion – it
will interfere with the normal exchange of gases and cellu-
lar fluids in the underlying cells" [29].
Our primary focus is on a 1973 study of morphological
changes associated with the insertion of a subcutaneous
Millipore filter in mice [30]. The salient aspects of the
experiment are as follows. The investigators inserted into
each mouse a Millipore filter 2 cm in diameter with a
given pore size. The results clustered into two distinct
groups. In what we call the small-pore group, the fraction
of mice with the sarcomas was 11/11, 6/10, and 8/10 for
implant pore sizes of 0.025, 0.05, and 0.10 μm respec-
tively. In the large-pore group no sarcomas developed in
groups of 9 mice with implant pore sizes of 0.45, 0.80,
3.00 and 8.00 μm, and 1 sarcoma arose in a group of 8
mice with pore size 3 μm and different (nylon reinforced)
type of implant. To investigate morphology, the investiga-
tors killed additional mice at either 1, 3, 5, and 10 months
after implantation and made the following observations.
In the large-pore group, the filter was invaded by inflam-
matory macrophages or their cytoplasmic processes, and
there was extensive intercellular contact throughout the
filter by cytoplasmic processes. In the small-pore group,
there was no invasion of the filter by cytoplasmic proc-
esses and thick fibrous capsules developed around
implants creating a sharp demarcation between normal
cells and the Millipore filter. Also in the small-pore group,
an early anaplastic sarcoma was detected at 10 months
and tumors developed by 22 months.
The main paradoxical result is the high incidence of sarco-
mas in the small-pore group and the negligible incidence
of sarcomas in the large-pore group. That these two
groups are distinct is confirmed by the presence or
absence of invasion by cytoplasmic processes. These
results are paradoxical under SMT because there is no
obvious mechanism for an association between pore size
and a genetic alteration.
There are two types of questions posed by these results
(summarized in Table 1). The first question is what aspect
of the difference in pore size is responsible for the differ-
ences in the incidence of sarcomas? The second is what is
the cellular mechanism underlying the induction of sarco-
mas by Millipore filter? We discuss a possible experiment
to address each question. The proposed experiments can-
not definitively determine the validity of any particular
theory. However it is hoped that it will provide new leads
for future investigation and spur bench scientists to con-
sider more studies outside the "box" of SMT.
What aspect of pore size is responsible for changes in incidence of 
sarcomas?
Before discussing an experiment, we discuss four possible
explanations that have been offered. One possibility is
that the incidence of sarcomas is related to the roughness
of the material, which increases with pore size. However,
despite noting that other experiments demonstrated an
association between roughness and sarcoma incidence,
the investigators concluded that for their experiment "this
increase [in roughness] is gradual with only a slight differ-
ence in roughness between 0.22 and 0.1 μm ...This hardly
explains the complete transition from negative to positive
tumorigenicity in that range." A second possibility is that
the incidence of sarcomas is related to surface area of the
filter, which is the area of the filter inside the pores and
hence approximately proportional to pore size. Again this
explanation does not explain the sudden change from no
incidence of tumors to high tumor incidence between fil-
ters with pore sizes of 0.22 and 0.1 μm; also it does not
explain other experiments that found no sarcomas when
Table 1: Possible experiments to investigate paradox associated with sarcomas and Millipore filters
Question Proposed experiment Rationale
What aspect of the implant is 
responsible for sarcomas?
2 × 2 × 2 × 2 factorial design involving surface area, roughness, 
electrostatic charge, pore size
A factorial design allows investigation of many factors at once.
How does the implant affect cellular 
changes?
Primary study: no implant versus small pore implant that 
induces sarcoma
Looking for salient differences in gene expression using multiple 
random validation and signatures with few genes
Secondary study: no implant versus large pore implant that 
does not induce sarcoma
Control study to determine if differences in gene expression 
could reliably be associated with histological changesBMC Cancer 2007, 7:151 http://www.biomedcentral.com/1471-2407/7/151
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inserted material was a powder. A third possibility is that
increased incidence in the incidence of sarcomas could be
related to changes in electric surface charges with to the
pore size. However the investigators noted that "since
...the tumorigenic and nontumorigenic filters were
hydrophilic and electropositive, the electric charge cannot
generally be considered the major determining factor in
foreign body carcinogenesis." A fourth possibility is that
the Millipore filters disrupted cell communication when
the holes were sufficiently small (a maximum of 0.10 μm)
to impede the transfer of critical molecules between cells.
Because sarcomas are cancers of the stroma, this explana-
tion does not fit the theory of stromal cells affecting epi-
thelial cells. However it is possible that the small pore size
filters could have blocked vital communication from one
part of the stroma to other.
Although the aforementioned evidence points to pore size
alone, without its impact on charge, surface area, or
roughness, as the most likely explanation for differences
in incidences of sarcomas, a more definitive study could
be conducted. A potential study design is a 2 × 2 × 2 × 2
factorial experiment involving 128 mice with the follow-
ing four factors: pore size (0.025 μm versus 0.45 μm),
roughness (two levels, perhaps either roughening or no
roughing of the filter surface or a smooth or rough plastic
lattice overlay related to [31]), surface area (either a single
filter or a stacked pair of filters as in [32]), and electro-
static charge (two levels, perhaps hydrophobic versus nor-
mal filters as in [33]), The sample size of 8 per each of 16
groups is designed to an detect extreme interactions,
namely a comparison between 9/10 in one group versus
1/10 in another group with power of .80 and Bonferroni
type I error of .05/15, for 15 comparisons versus a refer-
ence group. However we recommend analysis via logistic
regression to more systematically evaluate the factors.
What is the cellular mechanism underlying sarcomas induced by 
Millipore filters?
If researchers could understand the cellular mechanism by
which subcutaneous implants induce sarcomas without
any clear indication of a genetic change it would likely
greatly help in making progress toward understanding
carcinogenesis. Most of these experiments were conducted
decades ago. Since then biotechnology has improved
immensely.
We propose applying modern microarray technology to
study the changes associated with carcinogenesis in the
Millipore experiments involving different pore sizes. A
possible experiment is the following. Three hundred mice
would be randomized to three groups of 100 each, either
controls with no implants, implants of Milllipore filters
with small pores that yield high rates of sarcoma, and
implants of Millipore filters with large pores that yield vir-
tually no sarcomas. This sample size is larger than the size
of other microarray studies (per group) that have identi-
fied genes that contribute strongly to good performance.
From each mouse, investigators would take a sample of
subcutaneous tissue from the site of the implant (or cor-
responding site in control) at 5 weeks.
The primary analysis would involve comparing the gene
expression between controls and mice with filter implants
having small pores. The goal is to find the major changes
associated with the incidence of sarcoma. To this end, a
conservative analysis using multiple random validation
[34] is proposed. This method involves multiple random
splits of the training and test samples. On each random
split, a gene signature (classification rule) is selected in the
training sample and its classification performance is eval-
uated in the test sample. There are mathematical reasons
why most performance gain comes with the first few genes
included in the signature [35]. Therefore it is recom-
mended that performance be compared for signatures
involving 1, 2,3, 5 and 10 genes to determine the signa-
ture length such that good classification performance is
obtained and further gains in classification performance
with longer signatures are minor [33]. For the selected
gene signature, the histogram of genes selected on differ-
ent random training sets would be plotted to determine if
any genes are highly reproducible. The finding of highly
reproducible genes could provide an important lead to
the cellular mechanism underlying filter induced carcino-
genesis [36].
A secondary analysis would be performed comparing the
no implant group with a group receiving implants with
large pores. This analysis serves as a control to determine
if changes in gene expression could reliably be associated
with histological changes and to determine if there were
common cellular changes regardless of pore size.
Summary
Paradoxical results are not uncommon in studies of car-
cinogenesis. Ignoring these paradoxes is tantamount to
saying the prevailing theory holds in all instances except
the paradoxical cases. However ignoring "outliers" in data
analysis is not satisfying; it should be the last refuge when
all else fails. But more importantly, ignoring paradoxical
results means missing potentially exciting new avenues
for research. Rather than relegate the paradoxical results to
the periphery of investigations, they should be the center-
piece of a paradox-driven research portfolio.
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